Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 3/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796463 | 0.88 | THRA (0.37) | CYP4A11PPARACYP4F2THRBTHRA | |
| SCHEMBL19796563 | 0.86 | THRB (0.43) | THRBTHRARARBRARARARG | |
| SCHEMBL19796227 | 0.86 | MCL1 (0.39) | CYP4A11CYP4F2THRBTHRARARB | |
| SCHEMBL19804204 | 0.83 | CYP4A11 (0.38) | CYP4A11PPARACYP4F2NR1H2THRB | |
| SCHEMBL19796530 | 0.83 | THRB (0.44) | THRBTHRARARBRARARARG | |
| SCHEMBL19804115 | 0.82 | CA1 (0.38) | CYP4A11CYP4F2THRBRARBRARA | |
| SCHEMBL19796225 | 0.81 | MCL1 (0.40) | CYP4A11ALOX5CYP4F2THRBTHRA | |
| SCHEMBL19796460 | 0.81 | CYP4F2 (0.38) | CYP4A11ALOX5CYP4F2THRBTHRA | |
| SCHEMBL19796592 | 0.81 | RARB (0.39) | PPARATHRBTHRARARBRARA | |
| SCHEMBL19804610 | 0.81 | FFAR4 (0.40) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CYP4A11 1991/4885ALOX5 2671/4885PPARA 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.